SCHEMBL11030253

SCHEMBL11030253

CCOc1cc(CC)ccc1OC

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 3/20 0.56
CA2 P00918 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.52
KMT2A Q03164 2/20 0.51
KDM4E B2RXH2 4/20 0.50
PDE4A P27815 4/20 0.50
PDE4B Q07343 4/20 0.50
PDE4C Q08493 4/20 0.50
PDE4D Q08499 4/20 0.50
ALDH1A1 P00352 3/20 0.50
MAPT P10636 2/20 0.50
PTGS2 P35354 1/20 0.50
GAA P10253 1/20 0.50
MAPK1 P28482 1/20 0.49
ATM Q13315 1/20 0.48
PPARG P37231 1/20 0.47
PPARD Q03181 1/20 0.47
PPARA Q07869 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8171761 0.92 CALM1 (0.65) CALM1CA2KMT2AKDM4EALDH1A1
SCHEMBL2521728 0.90 CALM1 (0.51) CALM1KMT2AKDM4EPDE4APDE4D
SCHEMBL31428 0.87 CA2 (0.71) CA2KMT2AKDM4EALDH1A1PTGS2
SCHEMBL31275634 0.87 CA2 (0.71) CA2KMT2AKDM4EALDH1A1PTGS2
Ammonia Solution, Strong SCHEMBL266403 0.85 CA2 (0.68) CA2KMT2AKDM4EALDH1A1PTGS2
Water SCHEMBL8587595 0.85 CA2 (0.68) CA2KMT2AKDM4EALDH1A1PTGS2
SCHEMBL3972900 0.85 L3MBTL1 (0.54) CALM1CA2L3MBTL1KMT2AKDM4E
SCHEMBL2894087 0.85 KDM4E (0.55) CALM1CA2L3MBTL1KMT2AKDM4E
SCHEMBL12844009 0.85 CALM1 (0.61) CALM1CA2L3MBTL1KDM4EATM
SCHEMBL14244430 0.85 TTR (0.54) CALM1CA2L3MBTL1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240065264-A1 COMPOUNDS AND COMPOSITIONS FOR NEMATODE TREATMENT UNIV IOWA STATE RES FOUND INC (US) 2024-02-29 US disclosed
US-20110301144-A1 Kinase Antagonists THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-12-08 US disclosed
US-20100009963-A1 KINASE ANTAGONISTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-01-14 US disclosed
US-7585868-B2 Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-09-08 US disclosed
US-20070293516-A1 Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-12-20 US disclosed
US-4497815-A 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients Ozaki, Shoichiro (JP) 1985-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293516-A1 Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine MTOR, PI4KA, PIK3CA CALM1 2727/4885CA2 3891/4885L3MBTL1 1936/4885
US-20100009963-A1 KINASE ANTAGONISTS MTOR, RPS6KA3, AKT3 CALM1 1675/4885CA2 2766/4885L3MBTL1 2522/4885
US-20240065264-A1 COMPOUNDS AND COMPOSITIONS FOR NEMATODE TREATMENT HNMT, TUBB6, SGMS2 CALM1 1898/4885CA2 3103/4885L3MBTL1 3748/4885
US-20110301144-A1 Kinase Antagonists MTOR, RPS6KA3, AKT3 CALM1 1675/4885CA2 2766/4885L3MBTL1 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.